In a small, 25 man, but significant clinical trial of men with metastatic castrate-resistant prostate cancer (mCRPC) who also qualified for Radium-223 (Xofigo) it was shown that the level of pain a man has during the treatment could be used as a prognostic tool of his survival.
Use of a computerized brain exercise program designed to help people sharpen their cognitive function was found to be effective against chemo brain in breast Cancer Thrivers and will probably be useful for Cancer Thrivers with any chemo brain.
Get help with your drug co-pays
The 10-year outcomes from the RADAR phase 3 trial were recently published. The results showed that men with locally advanced prostate cancer who were treated with six months of androgen suppression therapy (ADT) and prostatic radiotherapy did not do as well as those who were treated with 18 months of ADT and radiation.
In an analysis of the NRG Oncology clinical trial NRG-RTOG 9202 it was shown that the interval of time to biochemical reoccurrence (PSA only or BCR), or the time it takes for previously treated prostate cancer to return as indicated by a prostate-specific antigen (PSA) rise, could be used as a surrogate endpoint for survival for men with locally advanced prostate cancer.
It was announced today that the Phase 3 ARCHES trial which evaluated XTANDI (enzalutamide) along with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone.
Prostate cancer treatments, particularly hormone therapy (ADT) can have a significant effect on speeding up the process of thinning and weakening the bones. There are some available treatments (Zoledronic acid aka Zoladex and denosumab aka Xgeva) which are designed to slow down or reverse this process; however, they are known to have many adverse side effects themselves. These side effects can include severe fractures of the femur which could limit survival and cataracts. For this reason, these treatments are usually used later, when men become castrate resistant and metastatic.
A recent finding shows that men with a Gleason score of 9–10 prostate cancer may derive a smaller survival benefit from androgen deprivation therapy (ADT) compared with those with Gleason score of 8.
According to Anthony V. D’Amico, MD, Ph.D., who is chief of the Division of Genitourinary Radiation Oncology and an institute physician at Dana-Farber Cancer Institute at Brigham and Women’s Hospital in Boston, “It makes logical sense that in these very aggressive prostate cancers, you need a multi-modality approach.”
At the ESMO 2018 Conference that was recently concluded, there was a report of the clinical experience of 100 men with metastatic castrate resistant prostate cancer (mCRPC) who were consecutively treated with Lu-177 PSMA-I&T Radioligand Therapy.
The understanding that the earlier Provenge is used in castrate resistant men with prostate cancer has led many men to ask why not use Provenge even earlier when they are still castrate sensitive? This question is an excellent one which follows the logical next step; however, the answer is surprising!
According to the results of the STAMPEDE trial.1 adding radiotherapy (radiation) to the current standard-of-care androgen deprivation therapy (ADT of hormone therapy) did not improve the overall survival in all men who are newly diagnosed metastatic prostate cancer.
Why are Zytiga and Xtandi added to ADT and not substituted for ADT? Do I really need to continue ADT when I use Xtandi or Zytiga?
Hormone Therapy (ADT) along with the chemotherapy drug Taxotere (docetaxel) and Estramustine improves survival in men with high risk, localized castration-resistant prostate cancer over ADT alone.
Epic Sciences and Genomic Health, Inc. today announced that a local Medicare Administrative Contractor that assesses molecular diagnostic technologies, has issued a positive final local coverage determination (LCD) for the Oncotype DX® AR-V7 Nucleus Detect™ test.
Recently released and unexpected findings have been announced, contrary to previous understandings, black men who received primary radiation therapy to treat their prostate cancer had lower rates of biochemical cancer recurrence than white men. They also had a lower rate of developing distant metastasis.
There has been much discussion as well as clinical trials about the use of personal genetic information, specifically the presence of mutations in the DNA repair genes such as BRACA2, with the successful use of PARP-Inhibitors and in confirming our understanding that the occurrences of these genetic mutations are an indication of a poor prognosis.
BRACA is not the only DNA repair pathway you nee to be aware of if you have Prostate Cancer. Learn about to other mutations you need to known.
It has been announced that the Phase III ARAMIS Trial (Androgen Receptor inhibiting Agent for Metastatic-free Survival) evaluating an investigational treatment known as darolutamide in men with Non-metastatic Castration-resistant Prostate Cancer (nM0) has successfully met its primary endpoint of extending the metastasis-free survival (MFS) of men compared to placebo.
In certain men newly diagnosed with Advanced Prostate Cancer, or metastatic prostate cancer debunking the tumor with radiation can increase survival advantage.
We know that the incidence of both cardiovascular disease (CVD) and prostate cancer increase with age, resulting in higher mortality. CVD is the second most common cause of death in men with prostate cancer [1,2] Hormone therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists like Lupron for treatment of prostate cancer has been linked to additional increases in CVD morbidity and mortality. This link is especially evident in the first year of treatment , and men with a history of CVD are at higher risk .
Degarelix, which is different from the (GnRH) agonists, is a GnRH receptor antagonist also approved for the treatment of men with advanced prostate cancer. However, good data is suggesting that degarelix might have a lower incidence of causing CVD than the GnRH agonists